AMRN
- Amarin Corporation plc
()
Overview
Company Summary
Amarin Corporation plc (AMRN) is a pharmaceutical company that focuses on the development and commercialization of therapeutics to improve cardiovascular health. The company's main product is Vascepa, a prescription omega-3 fatty acid medication.
Vascepa is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia. It is specifically used for patients with TG levels above 500 mg/dL, who are at a higher risk of cardiovascular complications like heart attacks and strokes.
Amarin Corporation engages in clinical trials and research to explore additional potential benefits of Vascepa. They are particularly interested in its impact on reducing cardiovascular events, such as heart attacks, strokes, and related deaths, in patients who are on statin therapy for cholesterol management.
The company also works on obtaining regulatory approvals and expanding the commercial availability of Vascepa in different regions around the world. This involves establishing partnerships with pharmaceutical distributors and healthcare providers to ensure broad market access.
In summary, Amarin Corporation focuses on the development, commercialization, and expansion of the use of Vascepa, a prescription medication that helps in reducing high levels of triglycerides and potentially reducing cardiovascular risks in patients.